Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells $161,000.00 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Samuel C. Blackman sold 10,000 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $16.10, for a total value of $161,000.00. Following the completion of the transaction, the insider now owns 1,057,535 shares of the company’s stock, valued at $17,026,313.50. This trade represents a 0.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Day One Biopharmaceuticals Trading Down 3.6 %

Shares of NASDAQ DAWN opened at $14.32 on Friday. Day One Biopharmaceuticals, Inc. has a 12-month low of $11.30 and a 12-month high of $18.07. The stock has a fifty day moving average price of $14.44 and a 200 day moving average price of $14.41.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.58. The company had revenue of $93.76 million during the quarter, compared to analyst estimates of $15.05 million. During the same quarter in the prior year, the company posted ($0.54) earnings per share. On average, equities analysts expect that Day One Biopharmaceuticals, Inc. will post -0.88 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DAWN. Mirae Asset Global Investments Co. Ltd. boosted its position in Day One Biopharmaceuticals by 38.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock valued at $51,000 after buying an additional 1,002 shares during the last quarter. Quest Partners LLC boosted its position in Day One Biopharmaceuticals by 9,238.6% in the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock valued at $108,000 after buying an additional 7,668 shares during the last quarter. SG Americas Securities LLC purchased a new position in Day One Biopharmaceuticals in the 2nd quarter valued at about $113,000. Point72 DIFC Ltd bought a new position in shares of Day One Biopharmaceuticals during the second quarter worth about $124,000. Finally, Hsbc Holdings PLC bought a new position in shares of Day One Biopharmaceuticals during the second quarter worth about $163,000. 87.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on DAWN. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. TD Cowen upgraded Day One Biopharmaceuticals to a “strong-buy” rating in a report on Monday, November 4th. Needham & Company LLC restated a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Bank of America upgraded Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and upped their price objective for the stock from $11.00 to $24.00 in a report on Thursday, August 1st. Finally, Wedbush restated an “outperform” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, July 25th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $35.71.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.